First, the shape of it
The math, meaning what the filed numbers actually show, is a business earning 86 cents of gross profit on every dollar of sales while sitting on a cash pile larger than a full year of revenue. The mood, meaning what the market is currently paying, prices that business at a price-to-earnings multiple in the 97th percentile of its own decade. The open question is whether the pipeline now assembling outside cystic fibrosis can grow fast enough to justify that premium before the CF franchise, which still funds everything, hits its natural ceiling.
How a single disease built a fortress
Vertex spent most of its first two decades as a company that kept almost making it. Then in October 2019, the FDA approved Trikafta, a pill that corrects the underlying protein defect in cystic fibrosis rather than just treating symptoms. The drug generated nearly $900 million in its first full quarter, as detailed in BioPharma Dive’s coverage of the Trikafta launch, and effectively made Vertex the only serious commercial player in a disease affecting a relatively small global patient population. Revenue compounded strongly through the early 2020s, per our data from the 10-K for fiscal year ended December 31, 2024. That is the fortress. The question the latest quarter raises is what gets built around it.
What the quarter actually changed
The 10-Q for the quarter ended June 30, 2026 shows total revenue of $3.33 billion, up 12% from the same quarter a year earlier. CF remains the engine: global CF revenue grew at a double-digit pace year-over-year, with ALYFTREK alone contributing $574 million for the quarter. That is a drug that did not exist in commercial form two years ago, already generating more revenue per quarter than many mid-sized pharmaceutical companies earn in a year.
But two other lines in the filing are worth watching, not for their size today but for their trajectory. CASGEVY, the gene-editing therapy Vertex developed with CRISPR Therapeutics for sickle cell disease and a related blood disorder, brought in a meaningful contribution for the quarter. JOURNAVX, a non-opioid pain medication launched in January 2025, added further revenue. Together those two products are small relative to the CF machine. Combined, they are on pace to exceed $500 million for the full year 2026, which management confirmed as a floor in the Q2 2026 earnings call. A year ago, non-CF revenue for the full year was a fraction of that figure. That is the change worth watching.
The number that does not move, and the one that did
Gross margin, the share of each sales dollar left after manufacturing costs, held at 85.6% for the quarter. For context, a typical consumer goods company keeps 30 to 40 cents on the dollar; Vertex keeps 86. That figure has been stable for years and reflects the economics of specialty drugs with no generic competition.
What did shift is the spending line. Combined R&D and operating expenses ran well above a billion dollars on a GAAP basis for the quarter, and management flagged further pressure in the second half of 2026 as the company funds simultaneous commercial launches in pain and kidney disease. Vertex also announced in July 2026 a $8.8 billion acquisition of Crinetics Pharmaceuticals, adding rare endocrine diseases as a fifth therapeutic area. That is a significant commitment for a company whose cash position, at $13.64 billion as of June 30, 2026 per the 10-Q filed for that quarter, means the deal consumes the better part of a year’s liquid reserves in a single transaction.
For a saver evaluating this business, the spending surge is not alarming on its own. It is the normal cost of converting a one-disease company into a multi-disease platform. The question is whether the bets pay off before the CF franchise, now covering an estimated 95% of eligible U.S. patients following April 2026 label expansions, approaches saturation.
What compounds from here
Three things are converging in the second half of 2026. The FDA set a November 30, 2026 decision date for povetacicept, a treatment for a kidney disease called IgA nephropathy, after accepting the application in June 2026. Interim data from the VX-147 kidney disease trial are expected by early 2027. And a competitive threat dissolved in August 2026 when Sionna Therapeutics reported that its CF candidate failed to show meaningful benefit when added to Trikafta, per Seeking Alpha’s coverage of the competitive landscape. The moat held.
Vertex raised its full-year 2026 revenue guidance to a range just above $13 billion, excluding the Crinetics deal. Our data show the stock trading at a price-to-earnings multiple of 35 times, against a decade median of 31 times. The math says the business is compounding steadily. The mood says the market is already paying for the next chapter. Whether the kidney and pain pipelines write that chapter on schedule is the question one quarter cannot answer, but this quarter at least confirmed the story is moving.
Reading the numbers
- $3.33 billion quarterly revenue, up 12% year-over-year, per the 10-Q for the quarter ended June 30, 2026. What it is: total sales for the quarter. What it means here: growth is accelerating slightly from the 8.9% full-year pace in FY2025. Everyday version: a shop that did $100 in sales last year did $112 this year, and is now running at a pace closer to $115.
- 85.6% gross margin, per the 10-Q for the quarter ended June 30, 2026. What it is: the share of each sales dollar remaining after manufacturing. What it means here: Vertex keeps 86 cents before paying for research, sales staff, or administration. Everyday version: a bakery that charges $10 for a loaf spends only $1.44 making it; the rest covers everything else and profit.
- $13.64 billion cash position, per the 10-Q for the quarter ended June 30, 2026. What it is: cash, short-term investments, and liquid securities on hand. What it means here: the company holds more than a full year of its own revenue in liquid assets, giving it the capacity to fund the Crinetics deal and ongoing R&D without borrowing. Everyday version: a household earning $80,000 a year with $85,000 in a savings account, before taking on a large planned expense.
- P/E of 35 times vs. decade median of 31 times (97th percentile) (our data). What it is: the price-to-earnings multiple, meaning how many dollars the market pays for each dollar of annual profit. What it means here: the stock is priced higher relative to its own history than at almost any point in the past decade. Everyday version: a rental property that historically sold for 15 times annual rent is now selling for 18 times, which is fine if rents are about to rise sharply, and expensive if they are not.
For the standing yardsticks on Vertex Pharmaceuticals Inc / Ma: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Vertex Pharmaceuticals Inc / Ma.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2024 (SEC EDGAR)
- MarketBeat: Vertex Q2 2026 earnings call highlights
- TIKR: Vertex Q2 2026 earnings call, the $8.8 billion bet
- BusinessWire: FDA label expansions for ALYFTREK and TRIKAFTA, April 1, 2026
- MarketBeat: Vertex FDA events, including povetacicept BLA acceptance
- Seeking Alpha: Vertex CF label expansion and competitive landscape
- BioPharma Dive: Trikafta launch history
